Delota Corp (SYDRF) fair value: what the stock is really worth
As of Sep 18, 2026: fair value of Delota Corp $0.09, price $0.10, upside -6.0%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Delota Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
59‑month range $0.0400 – $0.2332 · fair‑value band $0.0657 – $0.1209 · the $0.1000 price screens above the $0.0940 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Delota in your weekly email
Every Wednesday you see whether Delota is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Delota Corp. engages in the retail of various cannabis products in Canada. The company provides nicotine vape and alternative tobacco products. It sells its products through specialty vape stores under the 180 Smoke Vape Store brand e-commerce platform comprising www.180smoke.ca; and dispensaries under the Offside Cannabis brand.
Show more
Delota Corp. engages in the retail of various cannabis products in Canada. The company provides nicotine vape and alternative tobacco products. It sells its products through specialty vape stores under the 180 Smoke Vape Store brand e-commerce platform comprising www.180smoke.ca; and dispensaries under the Offside Cannabis brand. The company was formerly known as Spyder Cannabis Inc. and changed its name to Delota Corp. in November 2021. Delota Corp. is based in Concord, Canada.
Stock analysis
Delota Corp (SYDRF) currently trades at $0.1000, while our model-based Fair Value estimate is $0.0940, implying the stock looks roughly 6.4% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $0.8800 per share, and 23 of the 24 models we run sit above the $0.1000 price.
Bear case: the Asset-Based group reads lowest at $0.0300, and 1 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0657 (bear) to $0.1209 (bull), the price of $0.1000 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Delota Corp reported revenue of C$40.2M in FY2025 versus C$1.3M in FY2021, a compound +136.9%/yr. Reported net income was C$562K in FY2025.
Key figures
Market cap $2.9M · P/E ratio 10.0 · P/S ratio 0.14 · EPS (TTM) $0.0100 · Net margin 1.4% · Return on equity 71.5% · Return on assets (EBIT) −12.4% · Operating margin −4.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −6%, SYDRF screens richer than that median.
Fair Value models
Bear $0.0657Fair Value $0.0940Bull $0.1209
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.0100 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+18.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+134.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+69.1%
’17
’18
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−58.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−58.4%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−106% → 1%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 61 stocks
Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−6% · Below median
Profitability
Return on equity (TTM)72% · Top 25%
Return on assets5% · Top 25%
Net margin (TTM)2% · Above median
Operating margin (TTM)−4% · Bottom 25%
Growth and dividend
Revenue growth1% · Below median
Balance sheet
Debt / equity0.10× · Above median
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
P/E (TTM)10.0× · Cheapest 25%
P/B2.45× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Delota Corp Fair Value". https://www.fairvalue-calculator.com/stock/SYDRF
Frequently asked questions
Is Delota Corp (SYDRF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.0940 versus the last price from Sep 18, 2026 of $0.1000, about −6% upside (fairly valued).
What is the fair value of SYDRF?
Our model-based fair value for Delota Corp is $0.0940 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $0.1000.
What is the quality score of SYDRF?
Delota Corp has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Delota Corp (SYDRF)?
Our model-based price target is the fair value of $0.0940 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $0.0657, optimistic scenario $0.1209. It is a calculation from audited fundamentals, not an analyst target.
What is the Delota Corp stock forecast for 2026?
Our models put fair value at $0.0940, about −6% upside versus the last price from Sep 18, 2026 of $0.1000 (fairly valued). Cautious scenario $0.0657, optimistic scenario $0.1209. The calculation is refreshed regularly with new filings.
What is the revenue of Delota Corp (SYDRF)?
Delota Corp reported trailing-twelve-month revenue of about C$39.9M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Delota Corp (SYDRF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Delota Corp it is $0.0940 per share (as of Sep 24, 2026), against a price of $0.1000. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Delota Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SYDRF trades above its calculated fair value: price $0.1000, fair value $0.0940, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SYDRF?
No. The price is what the market pays today ($0.1000); the fair value is what the company's own numbers justify ($0.0940). For Delota Corp the two are $0.0060 per share apart. That gap is exactly why we show both numbers side by side.
How much is Delota Corp worth?
The market values Delota Corp at about $2.9M (market capitalisation, as of Sep 24, 2026). Per share that is $0.1000; our models calculate a fair value of $0.0940 per share.
What do the bullish and bearish scenarios say about SYDRF?
Our models span a range for Delota Corp: cautious scenario $0.0657, base $0.0940, optimistic $0.1209 per share (as of Sep 24, 2026, price $0.1000). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SYDRF?
Delota Corp trades at a price-to-earnings ratio of 10.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.0940 is built from several models across several years. Other multiples: P/B 2.5, P/S 0.1.
How solid is the balance sheet of Delota Corp (SYDRF)?
Balance-sheet figures for Delota Corp (as of Sep 24, 2026): return on equity 71.5%, debt of 0.10 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is SYDRF from its 52-week high?
Delota Corp trades at $0.1000, at its 52-week high of $0.1000 and 25% above the low of $0.0800 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0940 is for.
Which stocks are comparable to Delota Corp?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Delota Corp stock attractive at the current price?
The data as of Sep 24, 2026: price $0.1000, calculated fair value $0.0940 (−6%), Quality Score 56/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SYDRF calculated?
We run Delota Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0940, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Delota Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Delota Corp (SYDRF)?
The latest price we hold is from Sep 18, 2026 and stands at $0.1000. Our model-based fair value is $0.0940, about −6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Delota Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($0.0657 to $0.1209) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Delota Corp
How large is the market capitalisation of Delota Corp (SYDRF)?
The market capitalisation of Delota Corp is $2.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Delota Corp (SYDRF)?
The price-to-sales ratio of Delota Corp is 0.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Delota Corp (SYDRF)?
Earnings per share at Delota Corp are $0.0100 (price ÷ EPS = P/E 10.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Delota Corp (SYDRF)?
The net margin of Delota Corp is 1.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Delota Corp (SYDRF)?
The return on equity (ROE) of Delota Corp is 71.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Delota Corp (SYDRF)?
On an EBIT basis the return on assets of Delota Corp is −12.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Delota Corp (SYDRF)?
The operating margin of Delota Corp is −4.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Delota Corp (SYDRF)?
Revenue at Delota Corp is growing +1.2% versus a year earlier (3y avg +31.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Delota Corp (SYDRF) generate?
The free cash flow of Delota Corp is C$2.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Delota Corp (SYDRF) carry?
The net debt of Delota Corp is C$4.2M (fiscal year 2025, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Delota Corp in the live analysis
One click puts Delota Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026